| [1] |
东洁,陈博,李汉忠,等. Xp11.2易位/TFE3基因融合相关性肾癌六例报告并文献复习[J]. 中华泌尿外科杂志, 2016, 37(10): 745-748.
|
| [2] |
Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage[J]. Mod Pathol, 2014, 27(6): 875-886.
|
| [3] |
邱建星, 刘义,马明明, 等. Xp11.2易位/TFE3基因融合相关性肾癌的影像学表现：与肾嫌色细胞癌比较[J]. 中华放射学杂志, 2022, 56(9): 1015-1020.
|
| [4] |
李光杰,李宜桓,龙寿义,等. Xp11.2易位肾细胞癌误诊为肾盂癌1例并文献复习[J]. 现代肿瘤医学, 2023, 31(11): 2121-2123.
|
| [5] |
程瑾, 陈皓, 史景丽, 等. Xp11.2易位/TFE3基因融合相关性肾癌的CT和MRI表现[J]. 放射学实践, 2018, 33(8): 811-815.
|
| [6] |
李书强, 张玉石, 李汉忠. 肾细胞癌肾上腺转移19例临床分析[J]. 中华泌尿外科杂志, 2014, 35(6): 429-432.
|
| [7] |
Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI[J]. AJR Am J Roentgenol. 2011, 196(6): W706-W714.
|
| [8] |
Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors[J]. Am J Surg Pathol, 1984, 8(3): 163-169.
|
| [9] |
Mete O, Asa SL, Giordano TJ, et al. Immunohistochemical biomarkers of adrenal cortical neoplasms[J]. Endocr Pathol, 2018, 29(2): 137-149.
|
| [10] |
Ozcan A, Zhai Q, Javed R, et al. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin[J]. Arch Pathol Lab Med, 2010, 134(8): 1121-1129.
|
| [11] |
魏强. 靶向治疗时代:减瘤手术在转移性肾癌中的价值[J]. 现代泌尿外科杂志, 2014, 19(7): 484.
|
| [12] |
杨士杰, 王凌, 郭跃先, 等.晚期肾癌免疫治疗的研究进展[J]. 中华医学杂志, 2016, 96(46): 3774-3776.
|
| [13] |
Sun G, Chen J, Liang J, et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma[J]. Nat Commun, 2021, 12(1): 5262.
|
| [14] |
蔡梁, 沈亚丽. 立体定向体部放疗在晚期肾癌治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(10): 6 27-630.
|
| [15] |
Sharain RF, Gown AM, Greipp PT, et al. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study[J]. Hum Pathol, 2019, 87: 65-74.
|
| [16] |
Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network[J]. Ann Oncol, 2010, 21(9): 1834-1838.
|
| [17] |
Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841.
|
| [18] |
Choueiri TK, Kluger H, George S, et al. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy[J]. J Immunother Cancer, 2022, 10(11): e005780.
|
| [19] |
Keam SJ. Cadonilimab: first approval[J]. Drugs, 2022, 82(12): 1333-1339.
|
| [20] |
Gao X, Xu N, Li Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial[J]. Lancet Oncol, 2023, 24(10): 1134-1146.
|